Aquis Stock Exchange (AQSE) WITHDRAWAL FROM AQSE GROWTH MARKET |
Category Code: | MSCM |
TIDM: | AQSE |
LEI Code: | 213800AMGNBSOCOSDN11 |
Sequence No.: | 90392 |
EQS News ID: | 1157505 |
| |
End of Announcement | EQS News Service |
England will host New Zealand for two test matches in June for the home side's first games of the summer. It will be the first time that New Zealand, which leads the test rankings, has played tests in England since 2015. England beat New Zealand at Lord's in the 2019 World Cup final.
Venezuela's Juan Guaido is a "privileged interlocutor" but no longer considered interim president, European Union states said in a statement on Monday, sticking by their decision to downgrade his status. The EU's 27 states had said on Jan. 6 they could no longer legally recognise Guaido as after he lost his position as head of parliament following legislative elections in Venezuela in December, despite the EU not recognising that vote. Following the disputed re-election of President Nicolas Maduro in 2018, Guaido, as head of parliament, became interim president.
Furniture giant IKEA said it is on track to cut its emissions further after an 11% reduction in its climate footprint in the 12 months to the end of August, partly because of temporary store closures. Brand owner Inter IKEA said on Monday carbon emissions throughout the value chain - from the production of raw materials to customers' use and disposal - fell in its fiscal year (FY) 2020 to 21.2 million tonnes of CO2 equivalent. "Our expectation is that the trend that we started already in FY19 and continued in FY20 will also continue in FY21," Inter IKEA Chief Executive Jon Abrahamsson said in an interview.
Goldman Sachs sounds the alarm on some very hot tech stocks.
Frank Lampard has been sacked by Chelsea and is set to be replaced by the former PSG manager Thomas Tuchel
Electric Last Mile, Inc. (ELMS), a commercial electric vehicle (EV) solutions company, and Forum Merger III Corporation (NASDAQ: FIII, FIIIU, FIIIW) (Forum) today announced the nominees for the board of directors of the combined company that will result from the previously announced combination of Forum, a special purpose acquisition company, and ELMS. The director nominees bring decades of leadership across the technology, mobility and commercial delivery sectors. Following the proposed business combination, the common stock of the post-combination company is expected to continue to be listed on The Nasdaq Stock Market.
TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies in oncology, today announced the closing of an oversubscribed $100 million Series C financing. The financing round added new investors including funds and accounts managed by BlackRock, RA Capital Management, and two undisclosed healthcare-focused funds. Existing investors including founding investor Longwood Fund, 6 Dimensions Capital, Bessemer Venture Partners, GV, Novartis Venture Fund and Pitango HealthTech also participated in the round. Proceeds from this financing will be used to advance TScan’s TCR-T cell therapy pipeline for solid and liquid tumors into the clinic.
Momentus Inc. ("Momentus" or the "Company"), a commercial space company offering in-space infrastructure services, today announced its Board of Directors has appointed Dawn Harms, the Company’s Chief Revenue Officer, as a director and interim CEO effective immediately, following the resignation of director and founding CEO Mikhail Kokorich.
SweetWater Brewing Company today announced the introduction of a refreshingly tasty spin on hard seltzer with Oasis® Premium Hard Seltzer
Arizona Metals Corp. (TSXV:AMC, OTCQX:AZMCF) (the "Company" or "Arizona Metals") announces that it has qualified to trade on the OTCQX® Best Market. Arizona Metals Corp. upgraded to OTCQX from the OTCQB® Venture Market. In addition, the Company has secured DTC eligibility by The Depository Trust Company ("DTC") for electronic settlement and transfer of its common shares in the United States.
EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics License Application (BLA) for SYLVANT® (siltuximab for injection) was accepted by the China National Medical Products Administration (NMPA) and granted priority review. Siltuximab is a monoclonal antibody approved by the European Medicines Agency (EMA) and Food and Drug Administration (FDA) for the treatment of adult patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative, also known as idiopathic MCD (iMCD). iMCD is a rare, life-threatening and debilitating condition of the lymph nodes and related tissues. Siltuximab is listed in the first batch of New Drugs in Urgent Clinical Need Marketed Overseas by the NMPA.
Gensource Potash Corporation ("Gensource" or the "Company") (TSX.V: GSP) is pleased to provide an update on a previously announced in its January 13, 2021 news release proposed best efforts non-brokered private placement for gross proceeds of up to $10,000,000.00 (the "Offering"). As previously announced, the Offering will consist of the sale of up to 55,555,556 Common Shares of the Company ("Common Shares") at a price of $0.18 per Common Share.
AdvanSix Furthers Commitment To Sulfur Nutrition
Innovative Industrial Properties, Inc. (IIP), the first and only real estate company on the New York Stock Exchange (NYSE: IIPR) focused on the regulated U.S. cannabis industry, announced today that it closed on the acquisition of a property in Alachua, Florida, which comprises approximately 295,000 square feet of industrial space.
Sherritt International Corporation ("Sherritt") (TSX:S) today announced production results for the fourth quarter and full-year ended December 31, 2020 and provided guidance for expected production, unit costs and capital spending in 2021.
Positive high-level results from the ELEVATE-RR Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) met the primary endpoint demonstrating non-inferior progression-free survival (PFS) for adults with previously treated, high-risk chronic lymphocytic leukemia (CLL) compared to ibrutinib.
Faze Medicines appointed Philip Vickers, Ph.D., as its chief executive officer.
Wayfair Schedules Fourth Quarter 2020 Earnings Release and Conference Call
KSQ® Therapeutics Appoints Qasim Rizvi, MB ChB., M.B.A., as Chief Executive Officer
It's always the same two, you'll notice...
Yahoo Finance